You are here

Article Text

Article menu
Download PDFPDF
Correspondence
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs
  1. Edoardo Conticini1,
  2. Elena Bargagli2,
  3. Marco Bardelli1,
  4. Giuseppe Domenico Rana2,
  5. Caterina Baldi1,
  6. Paolo Cameli2,
  7. Stefano Gentileschi1,
  8. David Bennett2,
  9. Paolo Falsetti1,
  10. Nicola Lanzarone2,
  11. Francesca Bellisai1,
  12. Cristiana Barreca1,
  13. Roberto D'Alessandro1,
  14. Luca Cantarini1,
  15. Bruno Frediani1
  1. 1 Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy
  2. 2 Department of Medicine, Surgery and Neurosciences, Pneumology Unit, University of Siena, Siena, Italy
  1. Correspondence to Dr Edoardo Conticini, Rheumatology Unit, University of Siena, Siena 53100, Italy; conticini.edoardo{at}gmail.com

https://doi.org/10.1136/annrheumdis-2020-217681

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article by Monti et al,1 who evidenced, in a cohort of subjects affected by COVID-19, a low prevalence of patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).

    Despite a notable heterogeneity in different countries and even in different regions of the same country, a high lethality is reported among elderly patients with several comorbidities.2

    National and international registers have been created to collect patients affected by rheumatic diseases, as well as patients with interstitial lung disorders.3

    Since 20 February to 7 April 2020, we collected clinical data of 859 patients affected by different rheumatic diseases and sarcoidosis, treated with stable and full dosage of bDMARDs or tsDMARDs at Siena Rheumatology Unit and Siena Regional Referral Centre for Sarcoidosis.

    All patients underwent a telephone survey in order to establish their clinical status, the appearance of signs and symptoms of COVID-19 and the presence of …

    View Full Text

    Footnotes

    • Contributors EC conceived the paper. EC, EB and GDR wrote the paper. LC revised the paper. BF supervised the team. MB, SG, CBal, FB, CBar, RDA, PC, DB and NL collected clinical data.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles